About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a Healthcare company based in King Of Prussia (United States) founded in 1995, and was acquired by Durata Therapeutics in December 2009. Anti-infectives for hospital-based and community-acquired infections. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified. Its competitors include Vaxcyte, Vir Biotechnology and StrideBio; 3 of its 3 listed competitors have raised funding.
Company details
Vicuron Pharmaceuticals (formerly known as Versicor) is focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. It had two products anidulafungin for fungal infections and dalbavancin for Gram-positive infections. It was initially acquired by Pfizer in June 2005 and received marketing rights for anidulafungin with the brand name Eraxis. In December 2009, Durata Therapeutics acquired Vicuron and its other drug candidate dalbavancin, which had generated Phase 3 results in acute bacterial infections of the skin and skin structures at the time of acquisition.
- Headquarters King Of Prussia, United States
- Stage Acquired
- SectorsHealthcare
- Website vicuron.com
- Social LinkedIn
- Acquired by Durata Therapeutics (Dec 2009)
- InvestorsPfizer
& 1 more
- Acquired by
Investors in Vicuron Pharmaceuticals
Vicuron Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Pfizer and Durata Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Novel antibiotics for infectious diseases are developed by the company. | 2009 | duratatherapeutics.com | Chicago, United States |
Investor details for Vicuron Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Vicuron Pharmaceuticals
3 dated milestones of Vicuron Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Vicuron Pharmaceuticals is founded.
- Exit Acquired by Pfizer.
- Exit Acquired by Durata Therapeutics.
Competitors of Vicuron Pharmaceuticals
Vicuron Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Vaxcyte, Vir Biotechnology and StrideBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. |
Detailed competitors of Vicuron Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Vicuron Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vicuron Pharmaceuticals
Vicuron Pharmaceuticals was founded in 1995.
Vicuron Pharmaceuticals is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
Vicuron Pharmaceuticals (formerly known as Versicor) is focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. It had two products anidulafungin for fungal infections and dalbavancin for Gram-positive infections. It was initially acquired by Pfizer in June 2005 and received marketing rights for anidulafungin with the brand name Eraxis. In December 2009, Durata Therapeutics acquired Vicuron and its other drug candidate dalbavancin, which had generated Phase 3 results in acute bacterial infections of the skin and skin structures at the time of acquisition.
Vicuron Pharmaceuticals's top competitors include Vaxcyte, Vir Biotechnology and StrideBio.
Vicuron Pharmaceuticals has 2 investors. Key investors include Pfizer, and Durata Therapeutics.
Yes. Vicuron Pharmaceuticals was acquired by Durata Therapeutics in December 2009.